Business Description
Alcon Inc
ISIN : CH0432492467
Description
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | 4.84 | |||||
| Interest Coverage | 5.51 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.36 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.9 | |||||
| 3-Year EBITDA Growth Rate | 24.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.9 | |||||
| 3-Year FCF Growth Rate | 26.2 | |||||
| 3-Year Book Growth Rate | 1.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.28 | |||||
| Quick Ratio | 1.34 | |||||
| Cash Ratio | 0.44 | |||||
| Days Inventory | 191.99 | |||||
| Days Sales Outstanding | 70.63 | |||||
| Days Payable | 72.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -0.02 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.5 | |||||
| Operating Margin % | 11.01 | |||||
| Net Margin % | 10.2 | |||||
| FCF Margin % | 0.97 | |||||
| ROE % | 4.79 | |||||
| ROA % | 3.28 | |||||
| ROIC % | 4.51 | |||||
| ROC (Joel Greenblatt) % | 16.25 | |||||
| ROCE % | 3.82 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 42 | |||||
| Forward PE Ratio | 25.84 | |||||
| PE Ratio without NRI | 29.76 | |||||
| Price-to-Owner-Earnings | 198.37 | |||||
| PEG Ratio | 3.17 | |||||
| PS Ratio | 4.28 | |||||
| PB Ratio | 2.02 | |||||
| Price-to-Tangible-Book | 15.82 | |||||
| Price-to-Free-Cash-Flow | 433.14 | |||||
| Price-to-Operating-Cash-Flow | 112.62 | |||||
| EV-to-EBIT | 43.34 | |||||
| EV-to-EBITDA | 43.34 | |||||
| EV-to-Revenue | 4.69 | |||||
| EV-to-FCF | 474.46 | |||||
| Price-to-Graham-Number | 4.58 | |||||
| Earnings Yield (Greenblatt) % | 2.31 | |||||
| FCF Yield % | 0.23 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers